PRMT5
47 programs · 46 companies
Programs
47
Companies
46
Active Trials
43
Targeting PRMT5
| Drug | Company | Phase | MOA | Indications |
|---|---|---|---|---|
| Nirarelsin | Johnson & Johnson | Phase 2 | CeliacCervical Ca | |
| MRK-853 | Merck & Co | Phase 1 | Endometrial CaRSV | |
| Geliderotide | Sanofi | Phase 1/2 | DMD | |
| Capifutibatinib | Sanofi | Approved | MigraineNASH | |
| NVO-9615 | Novo Nordisk | Phase 2/3 | PVSCLC | |
| Suracagene | GSK | Phase 3 | CholangiocarcinomaPompe | |
| Elrarapivir | Vertex Pharma | NDA/BLA | Rett | |
| Darafutibatinib | BioNTech | Preclinical | OCD | |
| Daratuximab | BioMarin | Phase 1 | Prostate CaNarcolepsy | |
| INC-1261 | Incyte | Phase 1/2 | NMOSD | |
| Suracapivasertib | Blueprint Medicines | Preclinical | LGS | |
| Fixafutibatinib | Denali | Phase 3 | CTCLHS | |
| Elracapivasertib | Kymera | Phase 3 | Pancreatic CaDMD | |
| BEA-2615 | Beam | Phase 3 | EpilepsyEwing Sarcoma | |
| Bemainavolisib | Annexon | NDA/BLA | CKDHS | |
| 450-5704 | Astellas | Phase 2/3 | ThymomaGIST | |
| Zenorasimod | Clinuvel | Phase 2 | PompeCSU | |
| QUO-3159 | Quotient Ther | Approved | HST2D | |
| Motavorutinib | Affinia Ther | NDA/BLA | WMWet AMD | |
| COR-4726 | Correvio (Advanz) | Preclinical | ThymomaGastric Ca | |
| Mirisotorasib | Zevra Therapeutics | Phase 1/2 | Hemophilia ACeliac | |
| Datovorutinib | Imunon | Approved | ObesityADHD | |
| Tezezasiran | Volato Group | Phase 2 | MigraineADPKD | |
| Miricapivasertib | Compass Inc | Phase 3 | CTCLMM | |
| Sovaosocimab | Kiora Pharma | Phase 1 | MCLCKD | |
| SCI-8054 | Sciwind Bio | Phase 2/3 | Ewing SarcomaHuntington's | |
| Talafotisoran | Celgene (BMS) | NDA/BLA | Meso | |
| Polatapinarof | Hua Medicine | Phase 1 | Schizophrenia | |
| QUA-2029 | Quanta Ther | Phase 1/2 | PVGBM | |
| ORB-4389 | Orbital Ther | Phase 3 | PsASCLC | |
| FRE-IIT-815 | Fred Hutch | NDA/BLA | PV | |
| Datorelsin | Oxford BioMedica | NDA/BLA | PSP | |
| Tixatuximab | Rapafusyn | Phase 3 | MDDOCD | |
| GNF-1172 | Genfit | NDA/BLA | ALSHuntington's | |
| VAL-183 | Valneva | Phase 2 | LNAS | |
| BER-6819 | BerGenBio | Phase 2/3 | Gastric CaHeart Failure | |
| 417-6972 | OBI Pharma | Preclinical | CLL | |
| Tixanesiran | Evolva | Phase 2 | Bladder CaRSV | |
| Lisonesiran | Lundbeck | Phase 2 | CTCLMS | |
| LAB-7111 | Laboratorio Chile | NDA/BLA | NB | |
| Sotozumab | Waters Corp | Approved | HCC | |
| BRK-679 | Bruker | Approved | Endometrial CaSCLC | |
| Datozanubrutinib | West Pharma | NDA/BLA | MCCT2D | |
| EGI-7413 | Egis Pharma | Phase 1 | LN | |
| EUP-1431 | Eupraxia Pharma | Phase 2 | DLBCLMCC | |
| Bemafotisoran | Ginkgo Bioworks | Preclinical | NB | |
| Tixasacituzumab | Veeva Systems | Phase 1 | Gastric CaUrothelial Ca |